MA31167B1 - Inhibiteurs de l'activite de akt - Google Patents

Inhibiteurs de l'activite de akt

Info

Publication number
MA31167B1
MA31167B1 MA32146A MA32146A MA31167B1 MA 31167 B1 MA31167 B1 MA 31167B1 MA 32146 A MA32146 A MA 32146A MA 32146 A MA32146 A MA 32146A MA 31167 B1 MA31167 B1 MA 31167B1
Authority
MA
Morocco
Prior art keywords
inhibitors
akt activity
activity
compounds
arteritis
Prior art date
Application number
MA32146A
Other languages
English (en)
Inventor
Mark Andrew Seefeld
Meagan B Rouse
Dirk A Heerding
Simon Peace
Kenneth C Mcnulty
Dennis S Yamashita
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39682107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31167(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA31167B1 publication Critical patent/MA31167B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION CONCERNE DE NOUVEAUX COMPOSÉS CARBOXAMIDE HÉTÉROCYCLIQUES, AINSI QUE L'UTILISATION DE TELS COMPOSÉS EN TANT QU'INHIBITEURS DE L'ACTIVITÉ DE LA PROTÉINE KINASE B ET DANS LE TRAITEMENT DU CANCER ET DE L'ARTHRITE.
MA32146A 2007-02-07 2009-08-06 Inhibiteurs de l'activite de akt MA31167B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88858607P 2007-02-07 2007-02-07

Publications (1)

Publication Number Publication Date
MA31167B1 true MA31167B1 (fr) 2010-02-01

Family

ID=39682107

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32146A MA31167B1 (fr) 2007-02-07 2009-08-06 Inhibiteurs de l'activite de akt

Country Status (34)

Country Link
US (7) US8410158B2 (fr)
EP (1) EP2117523B1 (fr)
JP (3) JP4723677B2 (fr)
KR (3) KR101537825B1 (fr)
CN (1) CN101646427B (fr)
AR (1) AR066184A1 (fr)
AU (1) AU2008213694B2 (fr)
BR (1) BRPI0807146B8 (fr)
CA (1) CA2678255C (fr)
CL (1) CL2008000348A1 (fr)
CO (1) CO6220930A2 (fr)
CR (1) CR10995A (fr)
CY (1) CY1115535T1 (fr)
DK (1) DK2117523T3 (fr)
DO (1) DOP2009000196A (fr)
EA (1) EA018038B1 (fr)
ES (1) ES2501518T3 (fr)
HR (1) HRP20140790T1 (fr)
IL (1) IL200212A (fr)
JO (1) JO3134B1 (fr)
MA (1) MA31167B1 (fr)
MX (2) MX367398B (fr)
MY (1) MY164480A (fr)
NZ (1) NZ579177A (fr)
PE (1) PE20090058A1 (fr)
PL (1) PL2117523T3 (fr)
PT (1) PT2117523E (fr)
SG (1) SG193678A1 (fr)
SI (1) SI2117523T1 (fr)
TW (2) TWI381836B (fr)
UA (1) UA102992C2 (fr)
UY (1) UY30892A1 (fr)
WO (1) WO2008098104A1 (fr)
ZA (1) ZA200905363B (fr)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625890B2 (en) 2005-11-10 2009-12-01 Smithkline Beecham Corp. Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
JP5581219B2 (ja) 2008-01-25 2014-08-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
RU2572826C2 (ru) 2008-12-02 2016-01-20 Чиралджен, Лтд. Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US20110288142A1 (en) * 2009-01-30 2011-11-24 Chen Pingyun Y CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
WO2010090716A1 (fr) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Hétéroaryles et applications associées
WO2010091306A1 (fr) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Nouveaux promédicaments à base d'inhibiteurs cyp17 stéroïdiens/anti-androgènes
CA2767253A1 (fr) 2009-07-06 2011-01-13 Ontorii, Inc. Nouveaux precurseurs d'acide nucleique et leurs methodes d'utilisation
AU2010298277B2 (en) * 2009-09-23 2014-07-03 Novartis Ag Combination
CN102762098B (zh) 2009-09-23 2015-10-14 葛兰素史密斯克莱有限责任公司 组合
BR112012008274A2 (pt) 2009-10-08 2015-09-22 Glaxosmithkline Llc combinação
CA2777085A1 (fr) 2009-10-08 2011-04-14 Glaxosmithkline Llc Association pharmaceutique
WO2011060380A1 (fr) * 2009-11-14 2011-05-19 The Regents Of The University Of California L'état de mutation de pik3ca et l'expression de sash1 prédisent la synergie entre le lapatinib et un inhibiteur d'akt dans le cancer du sein her2 positif
CA2794153C (fr) 2010-03-25 2018-01-02 Glaxosmithkline Llc Derives d'indoline substitue comme inhibiteurs de perk
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
JP2013526578A (ja) 2010-05-21 2013-06-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組合せ
WO2011150044A1 (fr) * 2010-05-26 2011-12-01 Glaxosmithkline Llc Combinaison
MX2013001660A (es) 2010-08-11 2013-06-03 Millenium Pharmaceuticals Inc Heteroarilos y usos de los mismos.
WO2012021611A1 (fr) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Hétéroaryles et utilisations de ceux-ci
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
TW201307309A (zh) 2010-10-13 2013-02-16 Millennium Pharm Inc 雜芳基化合物及其用途
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
JP6100700B2 (ja) 2011-01-11 2017-03-22 ノバルティス アーゲー 組合せ
US20120184548A1 (en) 2011-01-19 2012-07-19 Romyr Dominique Carboxylic acid aryl amides
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
US20120184562A1 (en) 2011-01-19 2012-07-19 Kin-Chun Luk 1,6- and 1,8-naphthyridines
US20120184542A1 (en) 2011-01-19 2012-07-19 Kevin Anderson Pyrido pyrimidines
US8673905B2 (en) 2011-03-17 2014-03-18 Hoffmann-La Roche Inc. Imidazo pyrazines
WO2012177925A1 (fr) 2011-06-21 2012-12-27 The Board Institute, Inc. Inhibiteurs akt pour le traitement d'un cancer exprimant un gène de fusion magi3 - akt3
AU2012284265B2 (en) 2011-07-19 2017-08-17 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
WO2013096630A1 (fr) * 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Hétéroaryles et utilisations de ceux-ci
NZ628394A (en) * 2012-04-24 2016-02-26 Glaxosmithkline Ip No 2 Ltd Treatment method for steroid responsive dermatoses
JP6453212B2 (ja) 2012-07-13 2019-01-16 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． キラル制御
CN104684923B (zh) 2012-07-13 2018-09-28 株式会社新日本科学 手性核酸佐剂
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
JP6254169B2 (ja) 2012-09-28 2017-12-27 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
ES2619610T3 (es) 2012-10-16 2017-06-26 Janssen Pharmaceutica Nv Moduladores de ROR-gamma-t de quinolinilo enlazado con heteroarilo
CA2888485C (fr) 2012-10-16 2021-01-26 Janssen Pharmaceutica Nv Modulateurs de ror-gamma-t de type quinolinyle a liaison phenyle
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
IN2015DN03909A (fr) * 2012-10-22 2015-10-02 Glaxosmithkline Llc
AU2013352369B2 (en) 2012-11-30 2016-07-28 Novartis Ag. Novel pharmaceutical composition
EP2943199A1 (fr) 2013-01-09 2015-11-18 Glaxosmithkline Intellectual Property (No. 2) Limited Combinaison
CN105189488B (zh) 2013-02-27 2018-07-24 百时美施贵宝公司 用作溴区结构域抑制剂的咔唑化合物
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
HK1214252A1 (zh) * 2013-03-15 2016-07-22 Verseon Corporation 作為凝血酶抑制劑的鹵代吡唑
CN110179795A (zh) 2013-03-15 2019-08-30 维颂公司 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
CA2920317A1 (fr) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarqueurs pour le traitement de troubles neoplasiques a l'aide de therapies ciblant les androgenes
JP6355724B2 (ja) 2013-10-01 2018-07-11 ノバルティス アーゲー がんを治療するためのアフレセルチブと組み合わせたエンザルタミド
ES3063787T3 (en) * 2013-10-01 2026-04-20 Novartis Ag Composition comprising a 17 a-hydroxylase/c17,20 lyase (cyp17a1) inhibitor and an akt inhibitor
KR20160068948A (ko) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyt의 이차 알코올 퀴놀리닐 조절제
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
WO2015056180A1 (fr) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Dérivés d'indoline utilisés comme inhibiteurs de perk
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
ES2742843T3 (es) 2013-10-15 2020-02-17 Janssen Pharmaceutica Nv Moduladores de quinolinilo de ROR(gamma)t
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
BR112016008215A2 (pt) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por alquila de roryt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
ES2857848T3 (es) 2013-12-24 2021-09-29 Bristol Myers Squibb Co Compuestos tricíclicos como agentes antineoplásicos
WO2015108047A1 (fr) 2014-01-15 2015-07-23 株式会社新日本科学 Adjuvant d'acide nucléique chiral possédant une activité d'induction d'immunité, et activateur d'induction d'immunité
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
WO2015108048A1 (fr) 2014-01-15 2015-07-23 株式会社新日本科学 Adjuvant d'acide nucléique chiral ayant un effet antitumoral et agent antitumoral
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
EP3116546A1 (fr) * 2014-03-12 2017-01-18 Novartis AG Combinaison comprenant un inhibiteur de btk et un inhibiteur d'atk
CN104926801B (zh) 2014-03-22 2019-06-04 浙江大学 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
WO2015188073A1 (fr) 2014-06-06 2015-12-10 Research Triangle Institute Agonistes du récepteur de l'apeline (apj) et leurs utilisations
US10189810B2 (en) 2014-09-17 2019-01-29 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
WO2016059602A2 (fr) 2014-10-16 2016-04-21 Glaxo Group Limited Méthodes de traitement du cancer et compositions associées
TW201630907A (zh) 2014-12-22 2016-09-01 必治妥美雅史谷比公司 ＴＧＦβＲ拮抗劑
CN107405333A (zh) 2015-02-27 2017-11-28 维颂公司 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
EP3380097A2 (fr) 2015-08-28 2018-10-03 Novartis AG Combinaison pharmaceutique comprenant (a) l'inhibiteur au pi3k isoforme-alpha spécifique alpelisib (byl719) et (b) un inhibiteur à akt, de préférence mk-2206, afuresertib ou uprosertib, et son utilisation dans le traitement/la prévention du cancer
WO2017098421A1 (fr) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Composés benzothiadiazine
CN108602806B (zh) 2015-12-09 2022-07-12 研究三角协会 改进的爱帕琳肽受体(apj)激动剂及其用途
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2017153952A1 (fr) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited Dérivés de 5-sulfamoyl-2-hydroxybenzamide
EP3473628B1 (fr) * 2016-06-16 2019-12-11 Harbin Zhenbao Pharmaceutical Co., Ltd. Composé dihydropyrazole azépine servant d'inhibiteur d'akt
JP7104690B2 (ja) * 2016-10-12 2022-07-21 リサーチ トライアングル インスティテュート 複素環式アペリン受容体（ａｐｊ）アゴニスト及びそれらの使用
KR20190090824A (ko) 2016-12-01 2019-08-02 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 암을 치료하는 방법
EP3573619A4 (fr) 2017-01-27 2020-10-28 SignalRX Pharmaceuticals, Inc. Thiénopyranones et furanopyranones en tant qu'inhibiteurs de kinase, de bromodomaine et de points de contrôle
CN107011377B (zh) * 2017-05-03 2019-02-26 南通书创药业科技有限公司 一种β-羰基磷酸酯的制备方法
CN110831582B (zh) 2017-07-05 2023-08-11 诺华股份有限公司 药物组合物
UY37866A (es) 2017-09-07 2019-03-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
WO2019053617A1 (fr) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Composés chimiques
EP3725791B1 (fr) * 2017-12-13 2023-03-15 Harbin Zhenbao Pharmaceutical Co., Ltd. Sel servant d'inhibiteur d'akt et cristal de celui-ci
WO2020023340A1 (fr) 2018-07-23 2020-01-30 Signalrx Pharmaceuticals, Inc. Composés à molécule unique fournissant une inhibition multi-cible de btk et d'autres protéines et leurs méthodes d'utilisation
JP2022512706A (ja) 2018-10-16 2022-02-07 エフ．ホフマン－ラ ロシュ アーゲー 眼科におけるＡｋｔ阻害剤の使用
CA3118493A1 (fr) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion de til utilisant des inhibiteurs de la voie akt
AR117206A1 (es) 2018-11-30 2021-07-21 Glaxosmithkline Ip Dev Ltd Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer
JPWO2020130125A1 (ja) 2018-12-21 2021-11-04 第一三共株式会社 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
CN110031626A (zh) * 2019-04-02 2019-07-19 浙江理工大学 一种用于胃肠道间质肿瘤迁移的标志物ack1及其应用
WO2021018941A1 (fr) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Méthodes de traitement du cancer
CA3148115A1 (fr) 2019-08-08 2021-02-11 Laekna Limited Methode de traitement du cancer
IL320609A (en) 2019-08-26 2025-07-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
US20230147129A1 (en) 2020-03-27 2023-05-11 Som Innovation Biotech, S.A. Compounds for use in the treatment of synucleinopathies
CN111592531B (zh) * 2020-06-23 2023-08-15 上海鲲博玖瑞医药科技发展有限公司 福瑞塞替的制备方法
CN111620860B (zh) * 2020-06-23 2023-02-03 济南健丰化工有限公司 一种福瑞塞替的制备方法
WO2022069554A1 (fr) 2020-10-01 2022-04-07 Bayer Aktiengesellschaft Procédé de production de 4-bromofuran-2-carboxylates
US20250177352A1 (en) 2022-03-14 2025-06-05 Laekna Limited Combination treatment for cancer
IL315848A (en) 2022-03-31 2024-11-01 Astrazeneca Ab Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment
AR129423A1 (es) 2022-05-27 2024-08-21 Viiv Healthcare Co Compuestos útiles en la terapia contra el hiv
WO2024083716A1 (fr) 2022-10-17 2024-04-25 Astrazeneca Ab Combinaisons d'un serd pour le traitement du cancer
EP4615431A1 (fr) 2022-11-11 2025-09-17 Astrazeneca AB Polythérapies pour le traitement du cancer
EP4719399A1 (fr) 2023-06-02 2026-04-08 Arvinas Operations, Inc. Combinaisons d'agents de dégradation du récepteur des estrogènes et d'inhibiteurs d'akt
CN117486856B (zh) * 2023-11-02 2026-02-06 上海毕得医药科技股份有限公司 一种4-溴-5-(三氟甲基)噻吩-2-羧酸甲酯的合成方法

Family Cites Families (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1030415A (zh) * 1987-02-20 1989-01-18 山之内制药株式会社 饱和的杂环碳酰胺衍生物和它的制备方法
ES2005163A6 (es) 1987-04-14 1989-03-01 Lilly S A E Un procedimiento para la produccion de derivados de tiofen-2-carboxamida.
CA1336909C (fr) 1988-03-16 1995-09-05 Vittorio Vecchietti Derives heterocycliques
DE3810848A1 (de) 1988-03-30 1989-10-19 Boehringer Ingelheim Kg Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung
DE3927483A1 (de) 1989-08-19 1991-02-21 Boehringer Ingelheim Kg Neue substituierte heterocyclische fuenfringe, ihre herstellung und verwendung
US5258357A (en) * 1989-10-07 1993-11-02 Basf Aktiengesellschaft Carboxamides, their preparation and their use as herbicides
DE3933573A1 (de) 1989-10-07 1991-04-18 Basf Ag Carbonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
GB9201755D0 (en) 1992-01-28 1992-03-11 British Bio Technology Compounds
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AU674553B2 (en) 1992-10-14 1997-01-02 Merck & Co., Inc. Fibrinogen receptor antagonists
DE69325662T2 (de) * 1992-10-23 2000-02-10 Merck Sharp & Dohme Ltd., Hoddesdon Dopamin rezeptor subtyp liganden
FR2707295A1 (fr) 1993-06-07 1995-01-13 Rhone Poulenc Agrochimie Fongicides pyrazoles substitués en position 3 par un hétérocycle.
EP0712397B1 (fr) * 1993-08-06 1999-04-21 Smithkline Beecham Plc Derives amides employes comme antagonistes du recepteur 5ht1d
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US5668148A (en) * 1995-04-20 1997-09-16 Merck & Co., Inc. Alpha1a adrenergic receptor antagonists
JP3964478B2 (ja) * 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
BR9606546A (pt) * 1995-08-02 1998-07-14 Uriach & Cia Sa J Novas carboxamidas com atividade fungicida
KR100423590B1 (ko) * 1995-08-02 2004-09-10 호따. 우리아치에씨아. 에세. 아. 항진균활성을갖는신규피리미돈유도체
DE69634822T2 (de) 1995-08-22 2006-04-27 Japan Tobacco Inc. Amid-verbindungen und ihre anwendung
US6001866A (en) * 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1997012613A1 (fr) 1995-10-05 1997-04-10 Warner-Lambert Company Procede de traitement et de prevention des inflammations et de l'atherosclerose
US5972980A (en) * 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5942544A (en) * 1996-02-22 1999-08-24 Dupont Pharmaceuticals Company α-branched anilines, toluenes, and analogs thereof as factor Xa inhibitors
JP2000507593A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
AU706497B2 (en) 1996-04-03 1999-06-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2249650A1 (fr) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibiteurs de la farnesyl-proteine transferase
AU706150B2 (en) 1996-04-03 1999-06-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU704792B2 (en) 1996-04-03 1999-05-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036881A1 (fr) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibiteurs de la farnesyl-proteine transferase
WO1997036898A1 (fr) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibiteurs de la farnesyl-proteine transferase
EP0891333A1 (fr) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibiteurs de la farnesyl-proteine transferase
WO1997036897A1 (fr) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibiteurs de la farnesyl-proteine transferase
AUPO163896A0 (en) * 1996-08-14 1996-09-05 Resmed Limited Determination of respiratory airflow
WO1998037068A1 (fr) * 1997-02-21 1998-08-27 Bristol-Myers Squibb Company Derives d'acide benzoïque et composes apparentes utilises comme agents antiarythmiques
US5998336A (en) 1997-02-26 1999-12-07 The Board Of Trustees Of The Leland Stanford Junior University Ceramic/metal and A15/metal superconducting composite materials exploiting the superconducting proximity effect and method of making the same
ATE334975T1 (de) 1997-05-30 2006-08-15 Takeda Pharmaceutical Sulfonamidderivate, ihre herstellung und verwendung
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
AU751139B2 (en) * 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
DE19882892T1 (de) 1997-12-12 2001-02-22 Euro Celtique Sa Herstellung von 3-substituierten Adeninen und Imidazopyridinen
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AUPP433398A0 (en) 1998-06-25 1998-07-16 Australian National University, The Compounds and processes
US6192967B1 (en) * 1998-10-19 2001-02-27 Sunny En Liung Huang Collapsible auto shade
US6130333A (en) 1998-11-27 2000-10-10 Monsanto Company Bicyclic imidazolyl derivatives as phosphodiesterase inhibitors, pharmaceutical compositions and method of use
GB9827882D0 (en) 1998-12-17 1999-02-10 Smithkline Beecham Plc Novel compounds
DE19904396A1 (de) 1999-02-04 2000-08-10 Bayer Ag Substituierte Pyrazolbenzylamin-Derivate
DE19904397A1 (de) 1999-02-04 2000-08-10 Bayer Ag Verwendung von Pyrazol-Carbonsäureamiden
JP2000256358A (ja) 1999-03-10 2000-09-19 Yamanouchi Pharmaceut Co Ltd ピラゾール誘導体
TR200102944T2 (tr) 1999-04-13 2002-08-21 Basf Aktiengesellschaft İntegrin reseptör ligandları
EP1185509A2 (fr) * 1999-05-24 2002-03-13 Cor Therapeutics, Inc. INHIBITEURS DU FACTEUR Xa
JP2003500382A (ja) * 1999-05-24 2003-01-07 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子の阻害剤
JP2001247569A (ja) 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
WO2001038309A1 (fr) 1999-11-24 2001-05-31 Cor Therapeutics, Inc. INHIBITEURS DU FACTEUR Xa A BASE D'ACIDES β-AMINES, ASPARTIQUES ET DIAMINOPROPIONIQUES
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
EP1162196A4 (fr) 1999-12-27 2003-04-16 Japan Tobacco Inc Composes a cycles accoles et leur utilisation comme medicaments
WO2001056557A2 (fr) 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Compositions utiles comme inhibiteurs de erk
HUP0202332A2 (en) * 2000-02-05 2002-10-28 Vertex Pharma Pyrazole compositions useful as inhibitors of erk
CA2369076A1 (fr) 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Compositions de pyrazole utiles en tant qu'inhibiteurs d'erk
AU2001250783A1 (en) * 2000-02-29 2001-09-12 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
GB0011098D0 (en) 2000-05-08 2000-06-28 Black James Foundation Pharmaceutical compositions comprising protpn pump inhibitors and gastrin/cholecystokinin receptor ligands
AU6469401A (en) 2000-05-19 2001-11-26 Serono Reproductive Biology In Pharmaceutically active compounds and methods of use
US6589195B1 (en) * 2000-05-26 2003-07-08 Orthomerica Products, Inc. Modular adjustable prophylactic hip orthosis and adduction/abduction joint
AU2001268711A1 (en) * 2000-06-23 2002-01-08 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
WO2002007823A2 (fr) 2000-07-24 2002-01-31 Davide Riccardo Grassetti Inhibition d'effets mutagenes de cancerogenes
GB0018758D0 (en) * 2000-07-31 2000-09-20 Smithkline Beecham Plc Novel use and compunds
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
WO2002064136A2 (fr) * 2001-01-26 2002-08-22 Chugai Seiyaku Kabushiki Kaisha Inhibiteurs de malonyl-coa decarboxylase utiles en tant que modulateurs metaboliques
JP2004532234A (ja) * 2001-04-27 2004-10-21 バーテックス　ファーマシューティカルズ　インコーポレイテッド トリアゾール由来キナーゼインヒビターおよびその使用
DE10223912A1 (de) * 2001-06-28 2003-01-16 Merck Patent Gmbh TN- und STN-Flüssigkristallanzeigen
US20030015823A1 (en) * 2001-07-18 2003-01-23 Hydranautics Method for forming a thick section, thermoset, solid casting
DE60226154T2 (de) * 2001-08-03 2009-05-20 Vertex Pharmaceuticals Inc., Cambridge Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
ATE491701T1 (de) * 2001-08-03 2011-01-15 Vertex Pharma Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
BR0212101A (pt) * 2001-08-24 2004-08-24 Pharmacia & Up John Company 7-aza [2.2.1] biciclo-heptanos substituìdos com heteroarila para o tratamento de doenças
DK1441724T3 (da) * 2001-09-27 2007-12-03 Serono Lab Fremgangsmåde til forögelse af endogene testosteronniveauer
US6794252B2 (en) * 2001-09-28 2004-09-21 Texas Instruments Incorporated Method and system for forming dual work function gate electrodes in a semiconductor device
WO2003035619A1 (fr) 2001-10-25 2003-05-01 Merck & Co., Inc. Inhibiteurs de la tyrosine kinase
US6897208B2 (en) 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
WO2003039529A1 (fr) 2001-11-07 2003-05-15 4Sc A.G. Agents antibacteriens selectifs
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
EP1472245A2 (fr) * 2002-02-06 2004-11-03 Vertex Pharmaceuticals Incorporated Composes heteroaryles utiles en tant qu'inhibiteurs de gsk-3
US7335779B2 (en) 2002-03-08 2008-02-26 Quonova, Llc Modulation of pathogenicity
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
GB0206861D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Medicaments
US20050154202A1 (en) 2002-04-05 2005-07-14 Hagmann William K. Substituted aryl amides
WO2003090751A1 (fr) * 2002-04-26 2003-11-06 Pfizer Products Inc. Inhibiteurs de metalloproteinase a base de pyrimidine-2, 4, 6-trione
AU2003240546A1 (en) * 2002-06-05 2003-12-22 Pharmacia And Upjohn Company Methods for identifying ligands using competitive binding 1h nmr experiments
GB0216224D0 (en) * 2002-07-12 2002-08-21 Glaxo Group Ltd Compounds
PL374970A1 (en) 2002-08-02 2005-11-14 Argenta Discovery Limited Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors
MXPA05001592A (es) * 2002-08-09 2005-05-05 Astrazeneca Ab Oxadiazoles como moduladores de receptor-5 de glutamato metabotropico.
US6649638B1 (en) * 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
EP1534680B1 (fr) * 2002-08-14 2012-02-22 Pharmaco Investments, Inc. Inhibiteurs de prenylation et leurs methodes de synthese et d'utilisation
AU2003268184A1 (en) * 2002-08-23 2004-03-11 Chiron Corporation Pyrrole based inhibitors of glycogen synthase kinase 3
DE10239443A1 (de) 2002-08-28 2004-03-11 Boehringer Ingelheim International Gmbh Blockiervorrichtung für ein Sperrspannwerk mit federbetätigtem Abtrieb
EP1398029A1 (fr) * 2002-09-10 2004-03-17 LION Bioscience AG Derivés de pyrazole,substitués en position 3 ayant une affinité envers le NR3B1 récepteur
EP1581527A4 (fr) 2002-12-13 2006-11-22 Smithkline Beecham Corp Mimetiques de la thrombopoietine
CN1747949A (zh) 2002-12-20 2006-03-15 法马西亚公司 无环吡唑化合物
JP2006517211A (ja) * 2003-02-10 2006-07-20 バイエル・ヘルスケア・アクチェンゲゼルシャフト Ｐｇｉ２アンタゴニストとして使用するためのビス（ヘテロ）アリールカルボキサミド誘導体
WO2004072018A1 (fr) 2003-02-12 2004-08-26 Takeda Pharmaceutical Company Limited Derive d'amine
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
EP1599447A1 (fr) * 2003-02-28 2005-11-30 Galderma Research & Development, S.N.C. Ligands modulant des recepteurs du type lxr
US7517887B2 (en) 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
UY28280A1 (es) 2003-04-21 2004-11-30 Pharmacia & Amp 2- hidroxi - 3- diaminoalcanos de benzamida
JP4716996B2 (ja) * 2003-05-26 2011-07-06 武田薬品工業株式会社 スルホピロール
CA2529154C (fr) 2003-06-20 2013-05-07 Galderma Research & Development, S.N.C. Nouveaux composes qui modulent les recepteurs de type ppar.gamma. et utilisations de ceux-ci dans des compositions cosmetiques ou pharmaceutiques
DE10331305A1 (de) 2003-07-10 2005-02-17 Siemens Ag Kommunikationssystem, Peer-to-Peer-Nachrichten-Filter-Rechner und Verfahren zum Verarbeiten einer Peer-to-Peer-Nachricht
FR2857666B1 (fr) 2003-07-15 2005-08-26 Oreal Composition tinctoriale comprenant a titre de coupleur un derive du furane et nouveaux derives du furane
CN1826121B (zh) 2003-07-23 2013-05-29 幸讬制药公司 苯基与吡啶基衍生物用于制备调控钙离子释放活化钙离子通道的药物的用途
WO2005019200A2 (fr) 2003-08-14 2005-03-03 Icos Corporation Derives d'arylpiperidine utilises en tant qu'antagonistes d'integrine vla-1 et utilisations de ceux-ci
CA2536470A1 (fr) 2003-08-15 2005-02-24 Vertex Pharmaceuticals Incorporated Compositions de pyrrole convenant comme inhibiteurs de c-met
WO2005019182A1 (fr) 2003-08-20 2005-03-03 Bayer Healthcare Ag Derives de pyrazolylmethylbenzamide utilises comme antagonistes du recepteur p2xt
EP1689393A4 (fr) 2003-10-06 2008-12-17 Glaxo Group Ltd Preparation d'azabenzimidazoles 1,7-disubstitues comme inhibiteurs de kinases
EP1670466A4 (fr) 2003-10-06 2007-04-25 Glaxo Group Ltd Preparation d'azabenzimidazoles trisubstitues en position 1,6,7 servant d'inhibiteurs des kinases
US20050192314A1 (en) * 2003-11-13 2005-09-01 Ambit Biosciences Corporation Urea derivatives as C-kit modulators
CA2546754A1 (fr) 2003-11-21 2005-06-09 Array Biopharma Inc. Inhibiteurs de la proteine kinase akt
US8652089B2 (en) 2004-01-19 2014-02-18 Arthrex, Inc. System for distending body tissue cavities by continuous flow irrigation
US20080293716A1 (en) 2004-01-30 2008-11-27 Smithkline Beecham Corporation Chemical Compounds
WO2005077345A1 (fr) 2004-02-03 2005-08-25 Astrazeneca Ab Composes pour le traitement de la maladie du reflux gastro-oesophagien
WO2005077373A2 (fr) 2004-02-03 2005-08-25 Astrazeneca Ab Nouveau traitement du reflux gastro-oesophagien pathologique ii
AR047894A1 (es) 2004-02-25 2006-03-01 Wyeth Corp Derivados de tiofeno como inhibidores de la proteina tirosina fosfatasa 1b (ptpasa 1b); metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por ptpasa 1b
MXPA06010520A (es) * 2004-03-30 2007-03-26 Chiron Corp Derivados de tiofeno sustituidos como agentes anticancerosos.
JP2007531354A (ja) * 2004-03-30 2007-11-01 松下電器産業株式会社 コンテンツ中継サーバ、コンテンツ中継システム、コンテンツ中継方法及びそのプログラム
EP1730128A1 (fr) 2004-03-31 2006-12-13 Exelixis, Inc. Modulateurs de kinases de lymphomes anaplasiques (alk) et methodes d'utilisation
JP2005336172A (ja) 2004-04-26 2005-12-08 Japan Tobacco Inc 腎虚血再灌流障害治療又は予防薬
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
US20080119456A1 (en) * 2004-05-29 2008-05-22 Trond Ulven Substituted Thiazoleacetic Acid as Crth2 Ligands
EP1765332A2 (fr) * 2004-06-17 2007-03-28 Cengent Therapeutics, Inc. Modulateurs a base d'azote trisubstitue de tyrosine phosphatases
WO2006004984A1 (fr) * 2004-06-30 2006-01-12 Vertex Pharmaceuticals Incorporated Azaindoles utilises comme inhibiteurs de proteine kinases
US7671077B2 (en) * 2004-07-19 2010-03-02 Leu-Fen Hou Lin Neuroprotective small organic molecules, compositions and uses related thereto
US20060019967A1 (en) * 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
US20060019968A1 (en) * 2004-07-24 2006-01-26 Laboratorios Dr. Esteve S.A. Use of compounds active on the sigma receptor for the treatment of neuropathic pain
US7269099B2 (en) 2004-07-30 2007-09-11 Bolt Technology Corporation Air gun
JP2006066488A (ja) * 2004-08-25 2006-03-09 Mitsubishi Electric Corp 半導体受光素子およびその製造方法
US7365385B2 (en) * 2004-08-30 2008-04-29 Micron Technology, Inc. DRAM layout with vertical FETs and method of formation
US20060043513A1 (en) * 2004-09-02 2006-03-02 Deok-Hoon Kim Method of making camera module in wafer level
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
US20060062453A1 (en) * 2004-09-23 2006-03-23 Sharp Laboratories Of America, Inc. Color highlighting document image processing
WO2006043518A1 (fr) 2004-10-18 2006-04-27 Santen Pharmaceutical Co., Ltd. Médicament pour le traitement de maladies neurologiques
JP2006120339A (ja) 2004-10-19 2006-05-11 Matsushita Electric Ind Co Ltd 高周波加熱電源装置
TW200619843A (en) 2004-10-20 2006-06-16 Sumitomo Bakelite Co Semiconductor wafer and semiconductor device
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
CN101048383A (zh) 2004-11-23 2007-10-03 惠氏公司 促性腺激素释放激素受体拮抗剂
CA2588961A1 (fr) * 2004-11-30 2006-06-08 Neurosearch A/S Nouveaux derives aryliques diazabicycliques utilises en tant que ligands cholinergiques
SE527990C2 (sv) 2004-12-06 2006-08-01 Mora Of Sweden Ab Isborr
AU2006210503B2 (en) 2005-02-03 2009-09-03 Irm Llc Compounds and compositions as PPAR modulators
JP2006232707A (ja) 2005-02-23 2006-09-07 Japan Tobacco Inc 癌転移抑制剤
WO2006110762A2 (fr) 2005-04-11 2006-10-19 Achillion Compositions pharmaceutiques et methodes d'inhibition de la replication du vhc
US20060252807A1 (en) * 2005-04-22 2006-11-09 Kalypsys, Inc. Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
JP2008543919A (ja) 2005-06-21 2008-12-04 アステックス・セラピューティクス・リミテッド 医薬化合物
US20060288588A1 (en) 2005-06-22 2006-12-28 Frank Morabito Garden tool
JP5345842B2 (ja) * 2005-06-23 2013-11-20 アステックス・セラピューティクス・リミテッド プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ
MA28394B1 (fr) 2005-06-24 2007-01-02 Genelabs Tech Inc Derives d'heteroaryle pour traitement des virus
WO2006136637A2 (fr) * 2005-06-24 2006-12-28 Eloy Antonio Martinez Albal Implant dentaire a couronne rotative
US8703805B2 (en) 2005-06-27 2014-04-22 Exelixis Patent Company Llc Modulators of LXR
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
GB0518237D0 (en) 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007052843A1 (fr) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited Compose amide heterocyclique et son utilisation
US7838676B2 (en) * 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
AU2006325746A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2007076423A2 (fr) 2005-12-22 2007-07-05 Smithkline Beecham Corporation INHIBITEURS D’ACTIVITE Akt
SI1962830T1 (sl) 2005-12-23 2013-07-31 Glaxosmithkline Llc Azaindolni inhibitorji kinaz Aurora
AR056882A1 (es) 2006-02-01 2007-10-31 Bayer Cropscience Sa Derivados del fungicida n- cicloalquil- bencil- amida
CN101484424B (zh) 2006-02-28 2014-05-14 达特神经科学(开曼)有限公司 治疗化合物
JP2007277230A (ja) 2006-03-15 2007-10-25 Tanabe Seiyaku Co Ltd 医薬組成物
CA2673299C (fr) 2006-12-21 2016-04-12 Sloan-Kettering Institute For Cancer Research Composes de pyridazinone pour le traitement de maladies proliferatives
CA2671766A1 (fr) 2006-12-22 2008-07-03 Encysive Pharmaceuticals, Inc. Modulateurs du recepteur du c3a et leurs procedes d'utilisation
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
WO2008098105A1 (fr) 2007-02-07 2008-08-14 Smithkline Beecham Corporation Inhibiteurs de l'activité de akt
WO2008121685A1 (fr) 2007-03-28 2008-10-09 Smithkline Beecham Corporation Procédés d'utilisation pour inhibiteurs d'activité akt
WO2008121786A1 (fr) 2007-03-29 2008-10-09 Smithkline Beecham Corporation Inhibiteurs de l'activité de akt

Also Published As

Publication number Publication date
KR20140140570A (ko) 2014-12-09
PT2117523E (pt) 2014-09-29
UA102992C2 (en) 2013-09-10
UY30892A1 (es) 2008-09-02
JP4723677B2 (ja) 2011-07-13
JP2010518110A (ja) 2010-05-27
CL2008000348A1 (es) 2008-08-18
AR066184A1 (es) 2009-08-05
US20160287561A1 (en) 2016-10-06
ZA200905363B (en) 2010-05-26
EA200970738A1 (ru) 2010-06-30
KR20090110866A (ko) 2009-10-22
DOP2009000196A (es) 2009-10-31
EA018038B1 (ru) 2013-05-30
JP2011126896A (ja) 2011-06-30
CY1115535T1 (el) 2017-01-04
EP2117523B1 (fr) 2014-06-25
TW201130490A (en) 2011-09-16
KR101537825B1 (ko) 2015-07-22
SI2117523T1 (sl) 2014-10-30
JP5010038B2 (ja) 2012-08-29
IL200212A0 (en) 2010-04-29
HK1132676A1 (en) 2010-03-05
CN101646427B (zh) 2013-06-12
US8410158B2 (en) 2013-04-02
US20090209607A1 (en) 2009-08-20
JP2012167096A (ja) 2012-09-06
IL200212A (en) 2015-07-30
KR20120130298A (ko) 2012-11-30
KR101521002B1 (ko) 2015-05-19
DK2117523T3 (da) 2014-09-08
CO6220930A2 (es) 2010-11-19
US8946278B2 (en) 2015-02-03
TWI507194B (zh) 2015-11-11
WO2008098104A8 (fr) 2009-07-30
TW200845964A (en) 2008-12-01
EP2117523A1 (fr) 2009-11-18
TWI381836B (zh) 2013-01-11
EP2117523A4 (fr) 2011-05-25
NZ579177A (en) 2012-01-12
US20130231378A1 (en) 2013-09-05
SG193678A1 (en) 2013-10-30
AU2008213694A1 (en) 2008-08-14
BRPI0807146B1 (pt) 2020-05-26
JO3134B1 (ar) 2017-09-20
US8273782B2 (en) 2012-09-25
PE20090058A1 (es) 2009-04-03
HRP20140790T1 (hr) 2014-10-10
JP5511879B2 (ja) 2014-06-04
US20110071182A1 (en) 2011-03-24
WO2008098104A1 (fr) 2008-08-14
CA2678255A1 (fr) 2008-08-14
US20150152092A1 (en) 2015-06-04
PL2117523T3 (pl) 2014-11-28
AU2008213694A2 (en) 2010-06-24
MY164480A (en) 2017-12-29
CN101646427A (zh) 2010-02-10
CA2678255C (fr) 2014-06-03
ES2501518T3 (es) 2014-10-02
US20100041726A1 (en) 2010-02-18
BRPI0807146A2 (pt) 2014-04-15
CR10995A (es) 2009-10-16
AU2008213694B2 (en) 2013-07-04
MX367398B (es) 2019-08-20
US20100267759A1 (en) 2010-10-21
BRPI0807146B8 (pt) 2021-05-25
MX2009008550A (es) 2009-11-09

Similar Documents

Publication Publication Date Title
MA31167B1 (fr) Inhibiteurs de l'activite de akt
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
MA33606B1 (fr) Dérivés de pyrimidine en tant qu'inhibiteurs de protéine tyrosine kinase 2
MA29935B1 (fr) Inhibiteurs de l'activite de akt
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
EA200971077A1 (ru) Гетероциклические модуляторы киназы
TN2012000073A1 (fr) Derives des l-(piperidine-4-yl) pyrazole servant de modulateurs de gpr119
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
MA31090B1 (fr) Derives de dihydropyridine utiles en tant qu'inhibiteurs de la proteine kinase
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
MA27933A1 (fr) Inhibiteurs de l'activite de akt
EA200802054A1 (ru) Ингибиторы фермента
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
BR112013008140A8 (pt) "compostos imidazotriazinona".
TN2009000142A1 (en) Bicyclic triazoles as protein kinase modulators
EA201000149A1 (ru) Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз
EA200900783A1 (ru) Соединения и композиции в качестве ингибиторов киназы
MA31336B1 (fr) Inhibiteurs de pi3k alpha a base de pyridopyrimidinone
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
HRP20060166A2 (en) Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
EA200801580A1 (ru) Новые производные пирониндола и способ их получения